Novozymes A/S produces and sells industrial enzymes and microorganisms worldwide. More Details
Solid track record established dividend payer.
Share Price & News
How has Novozymes's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: NZYM B has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: NZYM B exceeded the Danish Chemicals industry which returned 5.3% over the past year.
Return vs Market: NZYM B underperformed the Danish Market which returned 28.5% over the past year.
Price Volatility Vs. Market
How volatile is Novozymes's share price compared to the market and industry in the last 5 years?
Simply Wall St News
23 hours ago | Simply Wall StNovozymes A/S Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
2 days ago | Simply Wall StHere's How We Evaluate Novozymes A/S's (CPH:NZYM B) Dividend
2 weeks ago | Simply Wall StIs Novozymes (CPH:NZYM B) A Risky Investment?
Is Novozymes undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: NZYM B (DKK391.5) is trading above our estimate of fair value (DKK251.82)
Significantly Below Fair Value: NZYM B is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: NZYM B is poor value based on its PE Ratio (35.6x) compared to the XE Chemicals industry average (20.7x).
PE vs Market: NZYM B is poor value based on its PE Ratio (35.6x) compared to the Danish market (16.3x).
Price to Earnings Growth Ratio
PEG Ratio: NZYM B is poor value based on its PEG Ratio (6x)
Price to Book Ratio
PB vs Industry: NZYM B is overvalued based on its PB Ratio (10.2x) compared to the XE Chemicals industry average (1.6x).
How is Novozymes forecast to perform in the next 1 to 3 years based on estimates from 18 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NZYM B's forecast earnings growth (5.9% per year) is above the savings rate (0.3%).
Earnings vs Market: NZYM B's earnings (5.9% per year) are forecast to grow slower than the Danish market (12% per year).
High Growth Earnings: NZYM B's earnings are forecast to grow, but not significantly.
Revenue vs Market: NZYM B's revenue (4.3% per year) is forecast to grow slower than the Danish market (6.5% per year).
High Growth Revenue: NZYM B's revenue (4.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NZYM B's Return on Equity is forecast to be high in 3 years time (28%)
How has Novozymes performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NZYM B has high quality earnings.
Growing Profit Margin: NZYM B's current net profit margins (21.6%) are higher than last year (21.4%).
Past Earnings Growth Analysis
Earnings Trend: NZYM B's earnings have grown by 2.2% per year over the past 5 years.
Accelerating Growth: NZYM B's earnings growth over the past year (0.8%) is below its 5-year average (2.2% per year).
Earnings vs Industry: NZYM B earnings growth over the past year (0.8%) exceeded the Chemicals industry -9.8%.
Return on Equity
High ROE: NZYM B's Return on Equity (28.6%) is considered high.
How is Novozymes's financial position?
Financial Position Analysis
Short Term Liabilities: NZYM B's short term assets (DKK6.6B) exceed its short term liabilities (DKK4.3B).
Long Term Liabilities: NZYM B's short term assets (DKK6.6B) exceed its long term liabilities (DKK5.0B).
Debt to Equity History and Analysis
Debt Level: NZYM B's debt to equity ratio (45.5%) is considered high.
Reducing Debt: NZYM B's debt to equity ratio has increased from 11.8% to 45.5% over the past 5 years.
Debt Coverage: NZYM B's debt is well covered by operating cash flow (78.9%).
Interest Coverage: NZYM B's interest payments on its debt are well covered by EBIT (152.6x coverage).
What is Novozymes's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: NZYM B's dividend (1.34%) is higher than the bottom 25% of dividend payers in the Danish market (1.33%).
High Dividend: NZYM B's dividend (1.34%) is low compared to the top 25% of dividend payers in the Danish market (3.58%).
Stability and Growth of Payments
Stable Dividend: NZYM B's dividends per share have been stable in the past 10 years.
Growing Dividend: NZYM B's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (47.7%), NZYM B's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: NZYM B's dividends in 3 years are forecast to be covered by earnings (51.2% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ms. Ester Baiget serves as Chief Executive Officer at Novozymes A/S Since February 1, 2020 and its President since 2020. She serves as the EMEA Commercial Director for Dow Elastomers, Electrical and Teleco ...
|Executive VP & CFO||1.08yrs||kr.4.20m||0.00036% |
|EVP of Strategy & Business Transfotmation||no data||kr.10.50m||no data|
|Executive Vice President of Consumer Biosolutions||4.67yrs||kr.7.70m||0.000050% |
|Executive Vice President of Agriculture & Industrial Biosolutions||4.67yrs||kr.7.60m||0.0036% |
|President & CEO||0.67yr||no data||no data|
|Executive Vice President of Operations||0.75yr||no data||no data|
|Head of Investor Relations||no data||no data||no data|
|Vice President of Global Sales & Marketing||no data||no data||no data|
|Head of Corporate Affairs & Sustainability - Novozymes Latin America||no data||no data||no data|
|VP and Head of New Business Development - Incubations & Acquisitions||no data||no data||no data|
|CSO and Executive VP of Research & Development||0.75yr||no data||no data|
|President of North American Region||11.17yrs||no data||no data|
Experienced Management: NZYM B's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
|Independent Director||13.75yrs||kr.500.00k||0.00023% |
|Employee Representative Director||10.75yrs||kr.500.00k||0.00013% |
|Independent Chairman||3.67yrs||kr.1.75m||0.00071% |
|Vice Chairman||0.67yr||no data||no data|
|Independent Director||3.67yrs||kr.750.00k||no data|
|Employee Representative Director||7.67yrs||kr.500.00k||0.00039% |
|Employee Representative Director||7.67yrs||kr.500.00k||0.00013% |
|Director||0.67yr||no data||no data|
|Director||0.67yr||no data||no data|
Experienced Board: NZYM B's board of directors are considered experienced (3.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Novozymes A/S's company bio, employee growth, exchange listings and data sources
- Name: Novozymes A/S
- Ticker: NZYM B
- Exchange: CPSE
- Founded: 1925
- Industry: Specialty Chemicals
- Sector: Materials
- Market Cap: kr.109.405b
- Shares outstanding: 280.24m
- Website: https://www.novozymes.com
Number of Employees
- Novozymes A/S
- Krogshoejvej 36
- Capital Region of Denmark
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|NVZM.F||OTCPK (Pink Sheets LLC)||Yes||Series B Shares||US||USD||Nov 2000|
|NZM2||DB (Deutsche Boerse AG)||Yes||Series B Shares||DE||EUR||Nov 2000|
|NZYM B||CPSE (OMX Nordic Exchange Copenhagen)||Yes||Series B Shares||DK||DKK||Nov 2000|
|0Q4U||LSE (London Stock Exchange)||Yes||Series B Shares||GB||DKK||Nov 2000|
|NZYMBC||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Series B Shares||GB||DKK||Nov 2000|
|NZYMB||SWX (SIX Swiss Exchange)||Yes||Series B Shares||CH||CHF||Nov 2000|
|NZYM||WBAG (Wiener Boerse AG)||Yes||Series B Shares||AT||EUR||Nov 2000|
|NZYM N||BMV (Bolsa Mexicana de Valores)||Yes||Series B Shares||MX||MXN||Nov 2000|
|NVZM.Y||OTCPK (Pink Sheets LLC)||UNSPONSORED ADR||US||USD||Feb 2003|
Novozymes A/S produces and sells industrial enzymes and microorganisms worldwide. The company offers agriculture solutions, including crop production, and animal health and nutrition solutions; liquefactio ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/26 22:32|
|End of Day Share Price||2020/10/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.